InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,896.40
(
-0.96%
)
Dow Jones
38,460.92
(
0.00%
)
Brent Oil
87.57
(
0.40%
)
Bitcoin
63,979.58
(
-0.47%
)
Post# of 15
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 01/16/2018 1:39:19 PM

Tuesday, January 16, 2018 1:39:19 PM

Post# of 15
TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression:

https://finance.yahoo.com/news/first-patient-dosed-phase-2-164500269.html

BMY is a co-sponsor of this single-arm trial, furnishing the Opdivo. The ct.g listing is at: https://clinicaltrials.gov/ct2/show/NCT03353675 .

*Since this trial was announced in Apr 2017, Transgene changed its ticker symbol from TRNG.PA to TNG.PA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up